P
PolyActiva
Uses a unique drug-polymer conjugate technology to enable site specific drug delivery from medical device components, such as implants, films, or fibers
About PolyActiva
PolyActiva is a biotechnology company specializing in the development of therapeutic products for ocular diseases. The company focuses on creating innovative ocular implants that provide sustained drug release, targeting conditions such as glaucoma and endophthalmitis. PolyActiva operates in the pharmaceutical and healthcare markets, primarily serving patients and healthcare providers who require advanced treatments for eye diseases. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary drug delivery systems. Revenue is generated through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies. PolyActiva's products are designed to offer high dose loadings and complete bioerosion, ensuring effective and safe treatment over extended periods. The company is headquartered in Melbourne, Australia, and collaborates with institutions like the Monash Institute of Pharmaceutical Sciences for its research activities.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Melbourne, Australia
- Employees
- 32
- Open positions
- None listed
- Dealroom signal
- 87.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | May 2025 | $26M | $104M | Brandon Capital Partners · Australian National Reconstruction Fund | ↗ |
| GRANT✓Other financing | May 2024 | $971K | — | Brandon Capital Partners | ↗ |
Growth signals
Latest recorded traffic for PolyActiva is 780 monthly website visits, down 51.2% over the last three months. PolyActiva's team grew 3.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Innovation Connections
Series A2 investors entered at this stage
Yuuwa Capital
Brandon Capital Partners
Series B and later1 investor entered at this stage
Australian National Reconstruction Fund
Other known investors2 additional known investors
Bionics Institute
CSIRO
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PolyActiva on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PolyActiva’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.